rs1536365

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_014363.6(SACS):​c.1656A>G​(p.Leu552Leu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.113 in 1,614,152 control chromosomes in the GnomAD database, including 11,253 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.088 ( 784 hom., cov: 33)
Exomes 𝑓: 0.12 ( 10469 hom. )

Consequence

SACS
NM_014363.6 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:13

Conservation

PhyloP100: -0.212
Variant links:
Genes affected
SACS (HGNC:10519): (sacsin molecular chaperone) This gene encodes the sacsin protein, which includes a UbL domain at the N-terminus, a DnaJ domain, and a HEPN domain at the C-terminus. The gene is highly expressed in the central nervous system, also found in skin, skeletal muscles and at low levels in the pancreas. This gene includes a very large exon spanning more than 12.8 kb. Mutations in this gene result in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), a neurodegenerative disorder characterized by early-onset cerebellar ataxia with spasticity and peripheral neuropathy. The authors of a publication on the effects of siRNA-mediated sacsin knockdown concluded that sacsin protects against mutant ataxin-1 and suggest that "the large multi-domain sacsin protein is able to recruit Hsp70 chaperone action and has the potential to regulate the effects of other ataxia proteins" (Parfitt et al., PubMed: 19208651). A pseudogene associated with this gene is located on chromosome 11. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.66).
BP6
Variant 13-23354956-T-C is Benign according to our data. Variant chr13-23354956-T-C is described in ClinVar as [Likely_benign]. Clinvar id is 130202.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-23354956-T-C is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.212 with no splicing effect.
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.121 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SACSNM_014363.6 linkc.1656A>G p.Leu552Leu synonymous_variant Exon 8 of 10 ENST00000382292.9 NP_055178.3 Q9NZJ4-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SACSENST00000382292.9 linkc.1656A>G p.Leu552Leu synonymous_variant Exon 8 of 10 5 NM_014363.6 ENSP00000371729.3 Q9NZJ4-1

Frequencies

GnomAD3 genomes
AF:
0.0886
AC:
13478
AN:
152192
Hom.:
783
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.0202
Gnomad AMI
AF:
0.0121
Gnomad AMR
AF:
0.0786
Gnomad ASJ
AF:
0.0822
Gnomad EAS
AF:
0.128
Gnomad SAS
AF:
0.128
Gnomad FIN
AF:
0.155
Gnomad MID
AF:
0.0728
Gnomad NFE
AF:
0.117
Gnomad OTH
AF:
0.0957
GnomAD3 exomes
AF:
0.112
AC:
28125
AN:
251274
Hom.:
1763
AF XY:
0.116
AC XY:
15690
AN XY:
135806
show subpopulations
Gnomad AFR exome
AF:
0.0177
Gnomad AMR exome
AF:
0.0826
Gnomad ASJ exome
AF:
0.0807
Gnomad EAS exome
AF:
0.115
Gnomad SAS exome
AF:
0.132
Gnomad FIN exome
AF:
0.158
Gnomad NFE exome
AF:
0.122
Gnomad OTH exome
AF:
0.115
GnomAD4 exome
AF:
0.116
AC:
169589
AN:
1461842
Hom.:
10469
Cov.:
34
AF XY:
0.117
AC XY:
85027
AN XY:
727218
show subpopulations
Gnomad4 AFR exome
AF:
0.0174
Gnomad4 AMR exome
AF:
0.0814
Gnomad4 ASJ exome
AF:
0.0806
Gnomad4 EAS exome
AF:
0.135
Gnomad4 SAS exome
AF:
0.130
Gnomad4 FIN exome
AF:
0.163
Gnomad4 NFE exome
AF:
0.118
Gnomad4 OTH exome
AF:
0.110
GnomAD4 genome
AF:
0.0885
AC:
13479
AN:
152310
Hom.:
784
Cov.:
33
AF XY:
0.0902
AC XY:
6721
AN XY:
74474
show subpopulations
Gnomad4 AFR
AF:
0.0201
Gnomad4 AMR
AF:
0.0785
Gnomad4 ASJ
AF:
0.0822
Gnomad4 EAS
AF:
0.127
Gnomad4 SAS
AF:
0.130
Gnomad4 FIN
AF:
0.155
Gnomad4 NFE
AF:
0.117
Gnomad4 OTH
AF:
0.0942
Alfa
AF:
0.107
Hom.:
1314
Bravo
AF:
0.0796
Asia WGS
AF:
0.113
AC:
392
AN:
3478
EpiCase
AF:
0.112
EpiControl
AF:
0.113

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Charlevoix-Saguenay spastic ataxia Benign:5
Nov 21, 2019
Natera, Inc.
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jun 14, 2016
Illumina Laboratory Services, Illumina
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jul 01, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Sep 21, 2015
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not specified Benign:3
-
Genetic Services Laboratory, University of Chicago
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

Likely benign based on allele frequency in 1000 Genomes Project or ESP global frequency and its presence in a patient with a rare or unrelated disease phenotype. NOT Sanger confirmed. -

-
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

-
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:3
Feb 22, 2016
Mayo Clinic Laboratories, Mayo Clinic
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Jul 06, 2018
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Spastic paraplegia Benign:1
Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Hereditary spastic paraplegia Benign:1
Dec 12, 2016
Genome Diagnostics Laboratory, The Hospital for Sick Children
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.66
CADD
Benign
8.0
DANN
Benign
0.55
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs1536365; hg19: chr13-23929095; COSMIC: COSV66536720; COSMIC: COSV66536720; API